Latest News and Press Releases

Longeveron announces Data Monitoring Committee for Phase 2b clinical trial in HLHS completed a risk-benefit assessment and recommended continuation.

Longeveron announced that a constructive Type C meeting with the U.S. FDA was held to discuss the ongoing development of laromestrocel in HLHS.

Longeveron supports the passing of the Mikaela Naylon Give Kids a Chance Act which reauthorizes the Rare Pediatric Disease Priority Review Voucher Program.

Dr. Joshua Hare, CSO and Exec Chairman interviewed on NPR's BioTech Nation, discussing potential breakthrough stem cell therapy for HLHS.

Longeveron® completes enrollment of pivotal Phase 2b clinical trial evaluating laromestrocel as a treatment for Hypoplastic Left Heart Syndrome (HLHS).

Longeveron reports positive long-term transplant-free survival (100% survival) data from a multi-year study in Hypoplastic Left Heart Syndrome (HLHS)

Longeveron® Lomecel-B 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society Mtg.

Longeveron management to present at the ROTH Healthcare Opportunities Conference. Speaking on Emerging Frontiers in Neuroscience panel and hosting 1x1s.

Longeveron announces positive Type C meeting with FDA, clarifying regulatory pathway to BLA submission for Lomecel-B for hypoplastic left heart syndrome.

Investigator meeting for ELPIS II, the on-going Phase 2b clinical trial evaluating Lomecel-B as a potential adjunct treatment for HLHS.